Cargando…

Profile of acotiamide in the treatment of functional dyspepsia

Efficacy of acotiamide for improving symptoms in patients with functional dyspepsia was shown by several clinical trials. In a randomized, double-blind, placebo-controlled, parallel-group comparative Phase III trial conducted in Japan, 100 mg of acotiamide three times a day for 4 weeks was more effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Masahiro, Iwasaki, Eisuke, Suzuki, Hidekazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827886/
https://www.ncbi.nlm.nih.gov/pubmed/27103837
http://dx.doi.org/10.2147/CEG.S72172
_version_ 1782426528705937408
author Ueda, Masahiro
Iwasaki, Eisuke
Suzuki, Hidekazu
author_facet Ueda, Masahiro
Iwasaki, Eisuke
Suzuki, Hidekazu
author_sort Ueda, Masahiro
collection PubMed
description Efficacy of acotiamide for improving symptoms in patients with functional dyspepsia was shown by several clinical trials. In a randomized, double-blind, placebo-controlled, parallel-group comparative Phase III trial conducted in Japan, 100 mg of acotiamide three times a day for 4 weeks was more effective than a placebo for improving symptoms, and quality of life. Acotiamide was well-tolerated treatment, with no significant adverse events. The aim of this review was to summarize the current evidence of the efficacy of acotiamide in the treatment of patients with functional dyspepsia.
format Online
Article
Text
id pubmed-4827886
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48278862016-04-21 Profile of acotiamide in the treatment of functional dyspepsia Ueda, Masahiro Iwasaki, Eisuke Suzuki, Hidekazu Clin Exp Gastroenterol Review Efficacy of acotiamide for improving symptoms in patients with functional dyspepsia was shown by several clinical trials. In a randomized, double-blind, placebo-controlled, parallel-group comparative Phase III trial conducted in Japan, 100 mg of acotiamide three times a day for 4 weeks was more effective than a placebo for improving symptoms, and quality of life. Acotiamide was well-tolerated treatment, with no significant adverse events. The aim of this review was to summarize the current evidence of the efficacy of acotiamide in the treatment of patients with functional dyspepsia. Dove Medical Press 2016-04-06 /pmc/articles/PMC4827886/ /pubmed/27103837 http://dx.doi.org/10.2147/CEG.S72172 Text en © 2016 Ueda et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Ueda, Masahiro
Iwasaki, Eisuke
Suzuki, Hidekazu
Profile of acotiamide in the treatment of functional dyspepsia
title Profile of acotiamide in the treatment of functional dyspepsia
title_full Profile of acotiamide in the treatment of functional dyspepsia
title_fullStr Profile of acotiamide in the treatment of functional dyspepsia
title_full_unstemmed Profile of acotiamide in the treatment of functional dyspepsia
title_short Profile of acotiamide in the treatment of functional dyspepsia
title_sort profile of acotiamide in the treatment of functional dyspepsia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827886/
https://www.ncbi.nlm.nih.gov/pubmed/27103837
http://dx.doi.org/10.2147/CEG.S72172
work_keys_str_mv AT uedamasahiro profileofacotiamideinthetreatmentoffunctionaldyspepsia
AT iwasakieisuke profileofacotiamideinthetreatmentoffunctionaldyspepsia
AT suzukihidekazu profileofacotiamideinthetreatmentoffunctionaldyspepsia